



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 2005)

UNUSUAL PRICE MOVEMENTS

This statement is made at the request of The Stock Exchange of Hong Kong Limited. The board of directors (the “Board”) have noted the increases in share price of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) during trading today and wish to state that save for disclosed herein, the Board are not aware of any reasons for such increases.

The Company has been notified by China Pharmaceutical Company Limited (“CPCL”), which is held as to 72.93% by Mr. Qu Jiguang (an executive Director of the Company) and as to 27.07% by 39 other shareholders, has acquired 340,000 shares of the Company at price range from \$0.87 to \$0.92 per share from market today. After the acquisition, the shareholding interest of CPCL in the Company was increased to 550,340,000 shares, representing approximately 27.15% of the issued share capital of the Company.

Save for the above, we confirm that there are no negotiations or agreements relating to intended acquisitions or realizations which are discloseable under rule 13.23 of the Listing Rules, neither is the board of the directors of the Company (the “Board”) aware of any matter discloseable under the general obligation imposed by rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board of Lijun International Pharmaceutical (Holding) Co., Ltd., the directors of which individually and jointly accept responsibility for the accuracy of this statement.

By Order of the Board
Lam Yiu Por
Company Secretary

Hong Kong, 26 February 2008

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Wu Zhihong, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xian Jun, Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.